Journal of Pediatric Epilepsy 2022; 11(04): 103-110
DOI: 10.1055/s-0042-1749343
Original Article

Evaluation of Bone Metabolism in Children Using Antiseizure Drugs: A Single-Center Experience and Review of the Literature

1   Pediatric Neurology Division, Faculty of Medicine, Giresun University, Maternity and Children Hospital, Giresun, Turkey
,
Ülkü Şiraz Gül
2   Department of Pediatric Endocrinology, Faculty of Medicine, Erciyes University, Kayseri, Turkey
,
Sultan Köker Aydın
3   Division of Pediatric Hematology, Department of Pediatrics, Antalya Training and Research Hospital, Antalya, Turkey
,
Adem Yasin Köksoy
4   Division of Pediatric Nephrology, Department of Pediatrics, Van Training and Research Hospital, Van, Turkey
› Author Affiliations

Abstract

The effect of anti-seizure drugs (ASDs) on bone mineral density (BMD) is a controversial topic. This study investigated the effect of monotherapy and polytherapy drugs separately. Patients with a history of epilepsy treated with the same ASDs for more than 6 months were included in the study. Data regarding patient demographics, biochemical markers related to bone metabolism (calcium, phosphorus, alkaline phosphatase, parathyroid hormone, vitamin D), and BMD with dual-energy X-ray absorptiometry (DXA) were collected and compared. In total, 104 children with epilepsy using valproic acid (VPA), levetiracetam (LEV), carbamazepine (CBZ) alone or in combination and 22 healthy controls were evaluated. The ages of the children (64 boys, 62 girls) ranged between 2 and 17, with a mean of 9.50 ± 4.03 years. BMD or Z-scores did not differ among the monotherapy groups or between them and the polytherapy group. The lowest mean Z-score was in the VPA group but without statistical significance. Alkaline phosphatase levels were significantly higher in the group using CBZ. Calcium levels significantly differed between the groups (p = 0.001). The CBZ and LEV groups had the lowest calcium levels. However, phosphorus and vitamin D measurements did not significantly differ by ASDs used. Unfortunately, low vitamin D levels were evident in all children with epilepsy and even among controls. Physical activity, sun exposure, and calcium intake might be recommended in children treated with ACDs and in combination with additional risk factors monitoring via DXA should be considered. Further studies in a large population are necessary to judge which ASDs are more at risk to reduce bone mineralization than others.



Publication History

Received: 03 March 2022

Accepted: 18 April 2022

Article published online:
02 August 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
  • References

  • 1 Prager C, Cross HJ. Diagnosis and management of the epilepsies in children. Prescriber 2018; 29 (04) 13-19
  • 2 Vestergaard P. Effects of antiepileptic drugs on bone health and growth potential in children with epilepsy. Paediatr Drugs 2015; 17 (02) 141-150
  • 3 Samaniego EA, Sheth RD. Bone consequences of epilepsy and antiepileptic medications. Semin Pediatr Neurol 2007; 14 (04) 196-200
  • 4 2019 ISCD official positions pediatric skeletal health assessment in children from infancy to adolescence. Accessed March 21, 2022 at: https://iscd.org/learn/official-positions/
  • 5 Minisola S, Colangelo L, Pepe J, Diacinti D, Cipriani C, Rao SD. Osteomalacia and vitamin D status: a clinical update 2020. JBMR Plus 2020; 5 (01) e10447
  • 6 Tutkavul K. Epilepsi ve Kemik Sağlığı (epilepsy and bone health). Epilepsi Dergisi 2018; 24 (Suppl. 01) 70-73
  • 7 Özemir ZA, Yalçın AD. Antiepileptik İlaçların Kemik Yoğunluğuna ve Metabolizmasına Etkileri (effects of antiepileptic drugs on bone density and metabolism). Epilepsi. J Turk Epilepsy Soc 2017; 23 (01) 1-8
  • 8 Gafni RI, Baron J. Overdiagnosis of osteoporosis in children due to misinterpretation of dual-energy X-ray absorptiometry (DEXA). J Pediatr 2004; 144 (02) 253-257
  • 9 Goksen D, Darcan S, Coker M, Kose T. Bone mineral density of healthy Turkish children and adolescents. J Clin Densitom 2006; 9 (01) 84-90
  • 10 Turan S, Topcu B, Gökçe İ. et al. Serum alkaline phosphatase levels in healthy children and evaluation of alkaline phosphatase z-scores in different types of rickets. J Clin Res Pediatr Endocrinol 2011; 3 (01) 7-11
  • 11 Sheth RD, Wesolowski CA, Jacob JC. et al. Effect of carbamazepine and valproate on bone mineral density. J Pediatr 1995; 127 (02) 256-262
  • 12 Akin R, Okutan V, Sarici U, Altunbaş A, Gökçay E. Evaluation of bone mineral density in children receiving antiepileptic drugs. Pediatr Neurol 1998; 19 (02) 129-131
  • 13 Kafali G, Erselcan T, Tanzer F. Effect of antiepileptic drugs on bone mineral density in children between ages 6 and 12 years. Clin Pediatr (Phila) 1999; 38 (02) 93-98
  • 14 Erbayat Altay E, Serdaroğlu A, Tümer L, Gücüyener K, Hasanoğlu A. Evaluation of bone mineral metabolism in children receiving carbamazepine and valproic acid. J Pediatr Endocrinol Metab 2000; 13 (07) 933-939
  • 15 Öner N, Kaya M, Karasalihoğlu S, Karaca H, Celtik C, Tütüncüler F. Bone mineral metabolism changes in epileptic children receiving valproic acid. J Paediatr Child Health 2004; 40 (08) 470-473
  • 16 Ecevit C, Aydoğan A, Kavakli T, Altinöz S. Effect of carbamazepine and valproate on bone mineral density. Pediatr Neurol 2004; 31 (04) 279-282
  • 17 Tekgul H, Dizdarer G, Demir N, Ozturk C, Tutuncuoglu S. Antiepileptic drug-induced osteopenia in ambulatory epileptic children receiving a standard vitamin D3 supplement. J Pediatr Endocrinol Metab 2005; 18 (06) 585-588
  • 18 Kumandas S, Koklu E, Gümüs H. et al. Effect of carbamezapine and valproic acid on bone mineral density, IGF-I and IGFBP-3. J Pediatr Endocrinol Metab 2006; 19 (04) 529-534
  • 19 Babayigit A, Dirik E, Bober E, Cakmakci H. Adverse effects of antiepileptic drugs on bone mineral density. Pediatr Neurol 2006; 35 (03) 177-181
  • 20 Coppola G, Fortunato D, Auricchio G. et al. Bone mineral density in children, adolescents, and young adults with epilepsy. Epilepsia 2009; 50 (09) 2140-2146
  • 21 Aksoy A, Sönmez FM, Deger O, Hosver I, Karagüzel G. The effects of antiepileptic drugs on the relationships between leptin levels and bone turnover in prepubertal children with epilepsy. J Pediatr Endocrinol Metab 2011; 24 (9-10): 703-708
  • 22 Serin HM, Koç ZP, Temelli B, Esen İ. The bone mineral content alterations in pediatric patients medicated with levetiracetam, valproic acid, and carbamazepine. Epilepsy Behav 2015; 51: 221-224
  • 23 Yaghini O, Tonekaboni SH, Amir Shahkarami SM, Ahmad Abadi F, Shariat F, Abdollah Gorji F. Bone mineral density in ambulatory children with epilepsy. Indian J Pediatr 2015; 82 (03) 225-229
  • 24 Osman NMM, Aziz RAA, Soliman GT, Mohamed AG. Bone mineral density evaluation of epileptic children on anti-convulsive medications. Egypt J Radiol Nucl Med 2017; 48 (04) 1083-1090
  • 25 Shin C, Lee NY, Han JY. et al. Effects of anticonvulsant monotherapy on bone mineral density in children. J Korean Child Neurol Soc 2018; 26 (04) 269-271
  • 26 Fong CY, Kong AN, Noordin M, Poh BK, Ong LC, Ng CC. Determinants of low bone mineral density in children with epilepsy. Eur J Paediatr Neurol 2018; 22 (01) 155-163
  • 27 McNamara NA, Romanowski EMF, Olson DP, Shellhaas RA. Bone health and endocrine comorbidities in pediatric epilepsy. Semin Pediatr Neurol 2017; 24 (04) 301-309
  • 28 Durá-Travé T, Gallinas-Victoriano F, Malumbres-Chacón M, Moreno-Gónzalez P, Aguilera-Albesa S, Yoldi-Petri ME. Vitamin D deficiency in children with epilepsy taking valproate and levetiracetam as monotherapy. Epilepsy Res 2018; 139: 80-84
  • 29 Xu Z, Jing X, Li G. et al. Valproate decreases vitamin D levels in pediatric patients with epilepsy. Seizure 2019; 71: 60-65
  • 30 Turan MI, Cayir A, Ozden O, Tan H. An examination of the mutual effects of valproic acid, carbamazepine, and phenobarbital on 25-hydroxyvitamin D levels and thyroid function tests. Neuropediatrics 2014; 45 (01) 16-21
  • 31 Inaloo S, Paktinat M, Saki F. et al. Bone mineral density loss in ambulatory children with epilepsy in spite of using supplemental vitamin D in Southern Iran: a case-control study. J Bone Miner Metab 2019; 37 (03) 537-544